Sweden needs new regulations and ways for collaboration to stay ahead in healthcare and the life sciences

In the report “Where is life science heading in the future?” Stockholm Science City claims that the future of healthcare will be predictive, preventive, participatory and personalized. Technology is pushing both life science and healthcare forward and the gap between basic science and clinical practice is shrinking. This creates opportunities for totally new types of therapies and health promoting solutions, but it also challenges current regulations and ways of working. Sweden has a leading role in healthcare and the life sciences today and has a good position to stay ahead in the race if Sweden’s national assets are used wisely.

As technology becomes increasingly important but also more advanced and expensive, it is important to secure access to both equipment and technical know-how. Hence, from a national perspective, it is essential to plan and coordinate infrastructure investments carefully to support the scientific and clinical communities. Cross-disciplinary collaborations are also an essential part of the recipe. As biology, medicine, engineering and computer science continue to converge, new ways of working together are needed. It is also necessary to prepare students for collaborative and cross-disciplinary work. This might need new organisational structures such as institutes and centres since paradigm changes are often met with resistance. In the healthcare system, it is necessary to adopt a patient-centric way of working instead of today’s system that is more discipline-bound to ensure best possible treatments. Here, strong leadership that is open to change and based on a sound knowledge of future opportunities is important. It is also important to form trustworthy models for collaboration between industry, healthcare providers and academia. Collaborations like that seen at SciLifeLab, where equipment, premises and expertise are shared between organisations, will be increasingly important if Sweden is to stay ahead in the future.

There is also a need for a national strategy for harmonising the regulations that steer how research and clinical work are allowed to be carried out since these areas become more intertwined and dependent on each other, allowing fast access to novel and personalised treatments. With increasing costs for new treatments, industry and healthcare also need to establish strategies and guidelines for precision medicine so that only those patients who can benefit from treatment get access to the them. Biopharmaceuticals are in many cases very expensive, and this raises concerns about future access to new therapeutics since the healthcare system is under pressure to maintain its current cost level.

To fully grasp the opportunities given by the digital revolution, the regulations for gathering and handling of medical data need to balance the benefits of advanced data utilisation with personal integrity. Increased gathering, improved access to, and methods for linking different types of data will be essential for increasing patient involvement, improving conditions for clinical trials, supporting the healthcare system and creating new opportunities for research and business. However, the new European General Data Protection Regulation will certainly affect the way data can be utilized and it is not clear today how this will affect data driven life science research and healthcare.

Sweden has many of the prerequisites for taking a leading role in the future thanks to our strong life science and ICT communities, together with extensive health data registries, biobanks and digital connectivity infrastructure. Non-hierarchical ways for collaboration is also well rooted in Swedish culture which is needed for cross-disciplinary and transcending collaborations. There is also a high degree of trust in Swedish society and a well organised healthcare system that can provide the stability needed for transformation in the health sector. However, it is important to fully take advantage of these assets and transform regulations and organisational structures. 

The report is based on presentations made and discussions occurring during a conference at Engelsbergs bruk, 4-5 May 2017, which was arranged by the Stockholm Science City Foundation and the Axel and Margaret Ax:son Johnson Foundation. The conference aimed to bring together representatives of different organisations and fields of interest to discuss the present status and future development of the life sciences. Various aspects ranging from global political standpoints to new technologies and ways of working were covered. Several challenges and opportunities for countries wanting to take a leading role in the life sciences were highlighted, with the focus on the future role of Sweden.

The report can be downloaded here.

Johan Gómez de la Torre
Johan Gómez de la Torre
Business Development Manager
Stockholm Science City Foundation

Stockholm Science City is an expert organisation that create relations and strengthen Stockholm’s competitiveness in the health area. We are a non-profit organization that increases cooperation between academy, industry and society and support the development of Stockholm as an internationally attractive environment for research and business.

- 2019-06-25

Scaling Up the Value: BioLamina

Uppsala BIO has an important role to connect and contribute to the overall growth of Life Sciences, nationally and internationally, both for academic institutions and companies.
Since the beginning of Testa Center, Uppsala BIOs team has as an external project coordinator role and has developed the application and selection process based on the BIO-X methodology.


Helena Ströberg, Uppsala BIO - 2019-06-19

Breaking down the numbers 2017-2018

The overall goal of Uppsala BIO is to contribute to Upsala's vision of 70,000 new jobs in 2050. Of these, at least 3500 jobs will be created in the life science sector.


Kristin Hellman, Uppsala BIO - 2018-08-22

Uppsala BIO helps Testa Center off to a flying start

Process based on successful BIO-X methodology.


Kristian Sandberg, Director of DDD, SciLifeLab in Uppsala - 2018-08-21

How to bridge the ‘Valley of Death’

The SciLifeLab Drug Discovery Model.


Erik Forsberg, Uppsala BIO - 2018-06-15

“You can make a holding company profitable, but it takes a bit of luck.”

This autumn, Lars Jonsson, CEO of UU Holding since 1998, retires and hands over a very successful investment business to his successor. “UU Holding is nothing short of a success story,” writes Uppsala BIO’s Erik Forsberg. Lars Jonsson has proven that it is possible to make a holding company profitable.


Magnus Engevik, Uppsala BIO - 2018-05-21

Uppsala’s innovation support system works! Award-winning Kontigo Care is the latest proof.

“With its high costs and huge suffering for those affected as well as their relatives, alcohol abuse is one of our major social problems. Kontigo Care’s work on digital biomarkers is one of the most exciting things I’ve witnessed during my career,” writes Uppsala BIO Buiness Developer Magnus Engevik.


Margaretha Gadnell, Uppsala BIO - 2018-04-25

Spotlight Uppsala’s unique resource!

Uppsala’s life science industry is healthy and developing well. More than 100 life science companies can be found here and in 2016 they employed about 5000 people and had a combined turnover of approximately SEK 27 billion.


Christina Wass, Project leader, Innovation Akademiska - 2017-12-13

“What happens in Vegas stays in Vegas…”

During 52 hours, staff from the Academic Hospital, AbbVie, Bristol Myers-Squibb and Microsoft worked together to develop and test new ideas and models for early diagnosis and better treatment of cancer. Now the experiences of Sweden's first “Innovation Race” can be summed up.


Lovisa Case - 2017-11-07

50 years of excellence – it all started with a collaboration between academia and industry!

2017 marks the 50 year anniversary of the RAST-method. Learn about the history and see how Uppsala BIO and UU Innovation are addressing future challenges in asthma and allergy diagnostics.


Johan Gómez de la Torre - 2017-10-25

Sweden needs new regulations and ways for collaboration to stay ahead in healthcare and the life sciences

Challenges and opportunities for countries wanting to take a leading role in life sciences, with focus on the future role of Sweden, was the topic of a seminar in May 2017. In our blog Johan Gómez de la Torre, Business Development Manager, Stockholm Science City digest the report.


Anna Ridderstad Wollberg - 2017-10-16

Call for proposals: A pull to transform inventions into innovations

How do we pull out the good ideas that may become new innovative products or treatments for the benefit of patients? Calls for project proposals may be the pull that is needed.


Madeleine Neil, Uppsala Health Summit - 2017-10-08

Uppsala Health Summit 2017: Time for the world to meet on Infectious Disease Threats  

10 – 11 October Uppsala Health Summit gathered 200 decision makers and experts from 30 different countries in a discussion about global threats from zoonotic infectious diseases. 


Karin Meyer, CEO, Swedish Pharmaceutical Society - 2017-10-02

EMA needs Sweden’s strong scientific environment

Karin Meyer, CEO, Swedish Pharmaceutical Society about what Sweden can offer the EMA and EU.


Margaretha Gadnell, Uppsala BIO - 2017-09-26

Check out EIT Health and its Uppsala activities

The purpose of EIT Health is to accelerate entrepreneurship and innovation for healthy living and active ageing in Europe.


Margareta Gadnell, Uppsala BIO - 2017-09-18

Fast-growing companies in Uppsala’s life science cluster

Between 2014 and 2015, the number of employees in this category increased by 11%. If we include 2013 as well, the increase is almost 20%.


Erik Forsberg, Uppsala BIO - 2017-08-28

Financial support and further action!

Our long-term goal is, as always, to contribute to growth by driving actions that complement those of the private and public sectors.


Annakarin Svenningsson, Uppsala BIO - 2017-08-15

Tough competition prior to relocation of EMA after Brexit

Among the arguments stressed in the Swedish application to convince other member states that Sweden and Stockholm is best suited to host the EMA, is the Swedish Medical Products Agency (MPA) in Uppsala.


- 2021-12-01


A visionary who wants to make a difference

Life Science is entering a new and exciting time, sometimes called the fourth industrial revolution. To meet these opportunities, the STUNS foundation has recruited Björn Arvidsson to fulfill the role of the new Managing director of the foundation's life science branch Uppsala BIO. Björn’s most recent engagement has been at the Swiss pharmaceutical and diagnostics giant Roche.